Objective: The aim of this study was to describe the current epidemiology of BSI in patients with cirrhosis, analyze predictors of 30-day mortality, and risk factors for antibiotic resistance. Methods: Cirrhotic patients developing a BSI episode were prospectively included at 19 centres in five countries from September 2014 to December 2015. The discrimination of mortality risk scores for 30-day mortality was compared by the area under the receiver operator-risk and Cox-regression models. Risk factors for multidrug-resistant organisms (MDRO) were assessed with a logistic regression model. Results: We enrolled 312 patients. Gram-negative bacteria, Gram-positive bacteria and Candida spp. were the cause of BSI episodes in 53%, 47% and 7% of cases, respectively. The 30-day mortality rate was 25% and best predicted by the SOFA and CLIF-SOFA score. In a Cox96 regression model, delayed (>24h) antibiotic treatment [HR 7.58 (95%CI 3.29-18.67), P<.001], inadequate empirical therapy [HR 3.14 (95%CI 1.93-5.12), P<.001] and CLIF-SOFA score [HR 1.35 (95%CI 1.28-1.43), P<.001] were independently associated with 30-day mortality. Independent risk factors for MDRO (31% of BSIs) were previous antimicrobial exposure [OR 2.91(95%CI 1.73-4.88), P<.001] and previous invasive procedures [OR 2.51 (95%CI 1.48-4.24),P=.001], whereas spontaneous bacterial peritonitis as BSI source was associated with a lowerodds of MDRO [OR 0.30 (95%CI 0.12-0.73), P=.008).Conclusions: MDRO account for nearly one-third of BSI in cirrhotic patients and often resulting in delayed or inadequate empirical antimicrobial therapy and increased mortality rates. Our data suggest that improved prevention and treatment strategies for MDRO are urgently needed in the liver cirrhosis patients.

A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients / Bartoletti, M.; Giannella, M.; Lewis, R.; Caraceni, P.; Tedeschi, S.; Paul, M.; Schramm, C.; Bruns, T.; Merli, M.; Cobos-Trigueros, N.; Seminari, E.; Retamar, P.; Muñoz, P.; Tumbarello, M.; Burra, P.; Torrani Cerenzia, M.; Barsic, B.; Calbo, E.; Maraolo, A. E.; Petrosillo, N.; Galan-Ladero, M. A.; D'Offizi, G.; Bar Sinai, N.; Rodríguez-Baño, J.; Verucchi, G.; Bernardi, M.; Viale, P.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - STAMPA. - (2017), pp. 1-18. [10.1016/j.cmi.2017.08.001]

A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients

Merli, M.;
2017

Abstract

Objective: The aim of this study was to describe the current epidemiology of BSI in patients with cirrhosis, analyze predictors of 30-day mortality, and risk factors for antibiotic resistance. Methods: Cirrhotic patients developing a BSI episode were prospectively included at 19 centres in five countries from September 2014 to December 2015. The discrimination of mortality risk scores for 30-day mortality was compared by the area under the receiver operator-risk and Cox-regression models. Risk factors for multidrug-resistant organisms (MDRO) were assessed with a logistic regression model. Results: We enrolled 312 patients. Gram-negative bacteria, Gram-positive bacteria and Candida spp. were the cause of BSI episodes in 53%, 47% and 7% of cases, respectively. The 30-day mortality rate was 25% and best predicted by the SOFA and CLIF-SOFA score. In a Cox96 regression model, delayed (>24h) antibiotic treatment [HR 7.58 (95%CI 3.29-18.67), P<.001], inadequate empirical therapy [HR 3.14 (95%CI 1.93-5.12), P<.001] and CLIF-SOFA score [HR 1.35 (95%CI 1.28-1.43), P<.001] were independently associated with 30-day mortality. Independent risk factors for MDRO (31% of BSIs) were previous antimicrobial exposure [OR 2.91(95%CI 1.73-4.88), P<.001] and previous invasive procedures [OR 2.51 (95%CI 1.48-4.24),P=.001], whereas spontaneous bacterial peritonitis as BSI source was associated with a lowerodds of MDRO [OR 0.30 (95%CI 0.12-0.73), P=.008).Conclusions: MDRO account for nearly one-third of BSI in cirrhotic patients and often resulting in delayed or inadequate empirical antimicrobial therapy and increased mortality rates. Our data suggest that improved prevention and treatment strategies for MDRO are urgently needed in the liver cirrhosis patients.
2017
Bacterial infections; Bloodstream infections; CLIF-SOFA; Liver cirrhosis; Multidrug-resistant pathogens; Microbiology (medical); Infectious Diseases
01 Pubblicazione su rivista::01a Articolo in rivista
A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients / Bartoletti, M.; Giannella, M.; Lewis, R.; Caraceni, P.; Tedeschi, S.; Paul, M.; Schramm, C.; Bruns, T.; Merli, M.; Cobos-Trigueros, N.; Seminari, E.; Retamar, P.; Muñoz, P.; Tumbarello, M.; Burra, P.; Torrani Cerenzia, M.; Barsic, B.; Calbo, E.; Maraolo, A. E.; Petrosillo, N.; Galan-Ladero, M. A.; D'Offizi, G.; Bar Sinai, N.; Rodríguez-Baño, J.; Verucchi, G.; Bernardi, M.; Viale, P.. - In: CLINICAL MICROBIOLOGY AND INFECTION. - ISSN 1198-743X. - STAMPA. - (2017), pp. 1-18. [10.1016/j.cmi.2017.08.001]
File allegati a questo prodotto
File Dimensione Formato  
bartoletti_prospective_2017.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.37 MB
Formato Adobe PDF
1.37 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1097271
Citazioni
  • ???jsp.display-item.citation.pmc??? 35
  • Scopus 72
  • ???jsp.display-item.citation.isi??? 67
social impact